Ketamine for PTSD: Evidence Summary
The evidence supports the use of ketamine for treatment-resistant PTSD, particularly when administered as repeated infusions (0.5 mg/kg IV) combined with psychotherapy, though this remains an off-label use requiring careful patient selection and monitoring.
Current Evidence Base
The strongest evidence comes from randomized controlled trials showing that repeated ketamine infusions significantly reduce PTSD symptoms compared to active controls 1. In the most rigorous trial, six ketamine infusions (0.5 mg/kg IV) over 2 weeks reduced PTSD severity by approximately 12 points more than midazolam on the CAPS-5 scale, with 67% of ketamine recipients achieving treatment response versus 20% with placebo 1. Effects were evident within 24 hours and the median time to loss of response was 27.5 days after completing the infusion series.
A 2026 meta-analysis of 12 studies (533 participants) found that greater improvement was associated with more psychotherapy sessions, more ketamine sessions, higher baseline symptom severity, and shorter treatment duration 2. However, most included studies were of poor quality, and when restricted to higher-quality studies, only baseline severity remained a robust predictor.
Clinical Application Algorithm
Patient Selection Criteria:
- Treatment-resistant PTSD (failed at least 2 adequate trials of evidence-based psychotherapy or pharmacotherapy)
- Age 18-50 years
- No active substance use disorders
- No contraindications to ketamine (uncontrolled hypertension, cardiovascular disease, elevated intracranial pressure)
- Baseline liver function tests obtained 3
Dosing Protocol:
- 0.5 mg/kg IV infusion over 40 minutes
- Six infusions over 2 consecutive weeks (3 per week) 1
- Alternative: Single doses of 0.5-1.0 mg/kg IM have shown efficacy 4
Monitoring Requirements:
- Continuous vital sign monitoring during and 2 hours post-infusion
- Baseline and periodic liver function tests with repeated dosing 3
- Assessment for dissociative symptoms using standardized scales
- PTSD symptom monitoring at 24 hours post-first infusion and weekly
Important Caveats and Safety Considerations
FDA Status and Off-Label Use:
Ketamine is FDA-approved only as an anesthetic, not for PTSD treatment 3. The FDA label explicitly warns about hepatobiliary dysfunction with recurrent use and notes that adverse psychiatric events can occur or persist days to weeks after exposure 3. This is off-label use requiring informed consent.
Guideline Perspective:
The 2023 VA/DoD PTSD guideline 5 does not recommend ketamine for PTSD treatment, as it focuses on evidence-based psychotherapies (prolonged exposure, cognitive processing therapy, EMDR) and specific SSRIs/SNRIs as first-line treatments. The 2022 VA/DoD depression guideline [6-6] supports ketamine only for treatment-resistant major depression, not PTSD specifically.
Adverse Effects Profile:
- Short-term: Dissociation, hemodynamic instability (hypertension, tachycardia), emergence reactions 3
- With repeated use: Hepatobiliary dysfunction, urinary tract symptoms (cystitis, dysuria), potential for dependence 3
- Psychiatric: Dissociative states may worsen acute stress responses if given immediately post-trauma 7
Timing Considerations:
Do not use ketamine in the immediate post-trauma period 7. Evidence suggests perioperative ketamine may be protective, but immediate post-trauma administration may worsen dissociative symptoms and acute stress responses. Reserve for chronic, treatment-resistant PTSD.
Practical Implementation
Combine ketamine with structured psychotherapy for optimal outcomes 2. The number of psychotherapy sessions correlates with better outcomes. Consider this an adjunctive intervention to facilitate psychotherapy engagement, not a standalone treatment.
Plan for maintenance: Response duration averages less than 4 weeks after a 2-week infusion course 1. Develop a plan for ongoing evidence-based treatment (trauma-focused psychotherapy, SSRIs/SNRIs) before initiating ketamine.
Monitor for abuse potential: Ketamine has known abuse liability. Screen for substance use history and monitor for signs of misuse, particularly given the need for repeated dosing.
Evidence Quality Limitations
The evidence base has significant limitations: most studies are small, heterogeneity is high, and the predominance of poor-quality studies limits confidence 2, 8. The 2024 meta-analysis found statistical significance only at treatment endpoint, not at 24 hours, when using rigorous statistical methods 8. This is emerging evidence, not established standard of care.